$1.18
-0.07-5.6%
Last update: Oct 30, 7:44 PM
Allogene Therapeutics Inc (ALLO) Stock Price, Quote, News & History
ALLONASDAQ
Cellectis (NASDAQ: CLLS) pivots to in vivo gene editing, extending cash runway to H2 2028. Read pipeline updates on .HEAL-101 & .HEAL-201.
You can purchase shares of Allogene Therapeutics (NASDAQ:ALLO) through any online brokerage.
Other companies in Allogene Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Allogene Therapeutics has a consensus price target of $7.68.
The stock price for Allogene Therapeutics (NASDAQ: ALLO) is $1.1999 last updated October 30, 2026 at 7:44 PM EDT.
There are no upcoming dividends for Allogene Therapeutics.
Allogene Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Allogene Therapeutics.
Allogene Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf"...
